IDH1 and central nervous system cancer: Granted, there have been a few markers that could serve as tools for diagnosis, prognosis, and prediction of the WHO grade of gliomas, such as 1p/19q chromosomal codeletion and IDH1/IDH2 mutations etc. But it is still commonly recognized that the prediction of clinical behavior, response to therapy, and outcome of glioma is quite challenging; hence, it is of great value and help to find more meaningful and easy-to-test biomarkers to achieve a more comprehensive and credible analysis and prediction of gliomas’ grading.